Ascendiant Capital maintains RenovoRx at Buy, raises price target to $15 from $14.50
Ascendiant Capital kept its Buy rating on RenovoRx and increased its price target to $15 from $14.50, a 3.4% rise. This implies a 1227.4% upside from the Nov 6 close of $1.13.
How this was made

The 30-second read
Why it matters
Analyst upgrade may trigger short‑term price rally but long‑term performance hinges on trial outcomes.
Market read
The price target raise is a modest catalyst for RNVR, offering a short‑term trade idea.
What to watch
Potential dilution from future financing rounds not addressed.
Background
RenovoRx is a clinical‑stage biotech focused on rare disease therapies.
Market effects
May lift sentiment in the biotech/clinical‑stage sector.
Limited to US biotech investors.
Minimal global impact.
Counterpoint
Target raise could be premature if upcoming trial data disappoints.
Key entities
- CompanyRenovoRx Inc.
Biotech firm receiving a price target increase.
- AnalystAscendiant Capital
Research firm that raised the price target.
